

Pfizer Inc
235 E. 42nd Street 235/4/1
New York, NY 10017
Tel 212 573 2798 Fax 212 672 7885
Email sieger@pfizer.com



Pfizer Pharmaceuticals Group

Richard Siegel, MD
Clinical Research Team Leader
Sexual Health

June 6, 2006

Division of Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane
Room 1061
Rockville, MD 20852

Petition No.: 2005 P-0423

Attn: Ms. Butler

We are writing you today to send you a copy (enclosed) of a letter that was originally mailed in December of last year. As you can see, this is a letter replying to the petition (HRG #1753) filed by Public Citizen's Health Research Group and Dr. Howard Pomeranz requesting that a black box warning be added to the USPI's of the phosphodiesterast type 5 (PDE5) inhibitor ED drugs warning of the potential for irreversible vision loss. As you can also see, the letter was originally mailed to an address we had on file at that time which we recently learned was an incorrect address.

We would appreciate this letter being posted to your website at your earliest possible opportunity so that it will be available to people who may be looking for the original petition. If you have any questions about this or need any additional information in order to post this letter, please let us know as soon as possible. Also, once the letter has been posted, we would appreciate your letting us know where (i.e. the URL) it will be available.

Thank you in advance for your cooperation with this matter.

Sincerely,

A handwritten signature in black ink, appearing to read "Richard Siegel, M.D.", written in a cursive style.

Richard Siegel, M.D.

2005P-0423

LET2